Non-Invasive Aesthetic Treatment Market Is Expected To Grow With The Compound Annual Growth Rate CAGR Of 16.5% By 2032

Healthcare

The revenue from injectables in 2021 was US$ 33.8 Bn and is expected to grow above 5X during the forecast period. The demand for injectables primarily comes from North America, Europe and APAC region, and these three regions collectively generated more than 85% revenue of injectables.

The non-Invasive aesthetic market revenues were estimated at US$ 53.3 Bn in 2021 and is anticipated to grow at a CAGR of 16.5% from 2022-2032, according to a recently published Fact.MR report. By the end of 2032, the market is expected to reach US$ 281.2 Bn.

The outbreak of Covid19 has impacted all the regions of the world as it affected medical tourism and the flow of medical services. As almost all the countries faced lockdown during the period, also patient appointments for non-invasive aesthetic treatments were temporarily halted.

Request Sample

Market Segments Covered in Non-Invasive Aesthetic Treatment Market Analysis

  • By Procedure :

    • Injectables
      • Botulinum Toxin
      • Calcium Hydroxylapatite
      • Hyaluronic Acid
      • Polymer Filler
      • Collagen
    • Skin Rejuvenation
      • Chemical Peel
      • Laser Skin Resurfacing
      • Photorejuvenation
    • Others
      • Hair Removal
      • Nonsurgical Fat Reduction
      • Sclerotherapy
      • Cellulite Treatment
  • By End Use :

    • Hospital/Surgery Center
    • MedSpa
    • Traditional Spa
    • HCP owned clinic
  • By Region :

    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • Japan
      • China
      • India
      • Thailand
      • South Korea
    • Latin America
      • Brazil
      • Mexico
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa

Competitive Analysis

Key players in the non-invasive aesthetic treatment market are focusing on growth strategies such as Improvement of existing technology, geographic expansion, product launch and product approval, to gain higher market share. Various development strategies help raise consumer awareness of new processes and products, such as product launches and collaborations.

The major players in the global non-invasive aesthetic treatment market are Allergan, Inc., Hologic Inc., Alma Lasers, Syneron Candela, Galderma S.A., Johnson & Johnson, Lumenis, Solta Medical, Cutera Inc., Revance Therapeutics Inc. and MerzPharma

  • In September, 2021 Lumenis, completed the US $1 billion sale of its surgical division to Boston Scientific Corporation, a medical device manufacturer. Lumenis intends to refocus and accelerate planned investments to support the growth of its fast-growing Aesthetic and Vision businesses, with a focus on R&D, worldwide sales and marketing channels, and business development.
  • In January 2021, Galderma launched Face for Change in partnership with The Skin Cancer Foundation and Dress for Success in the United States.
  • In January 2021, The Frax Pro system was made available by Candela, a prominent worldwide medical aesthetic device manufacturer. It is a non-ablative fractional device which is FDA-approved and CE-marked Also it is the first to offer dual-depth skin resurfacing with both Frax 1550TM and the revolutionary Frax 1940TM applicators. The two modalities work on distinct layers of the skin, promoting the production of new collagen and showing smoother, brighter skin.
  • In October 2020, Alma introduced its newest Alma Hybrid platform, which is aimed to investigate several options for using ablative, non-ablative, and thermal therapies on skin rejuvenation and scar revision, as well as assess their synergistic effects. As a result, the market is being fuelled by the availability of user-friendly, technologically improved non-invasive aesthetic treatment solutions.

Leave a Reply

Related Posts